Table 3.

Gout Rate Within Various Subgroups After Propensity Score Matching

Subgroup	GLP1 Agonist	SGLT2 Inhibitor
Men
Patients, n	57 807	57 807
Person-years, n	42 336	51 024
Events, n	397	325
Rate per 1000 person-years	9.38	6.37
HR (95% CI)	Reference	0.69 (0.60–0.80)
Women
Patients, n	61 294	61 294
Person-years, n	42 986	47 972
Events, n	262	167
Rate per 1000 person-years	6.10	3.48
HR (95% CI)	Reference	0.57 (0.47–0.69)
Age ≤60 y
Patients, n	90 733	90 733
Person-years, n	63 850	75 702
Events, n	450	342
Rate per 1000 person-years	7.05	4.52
HR (95% CI)	Reference	0.64 (0.56–0.74)
Age >60 y
Patients, n	31 248	31 248
Person-years, n	23 491	25 151
Events, n	238	170
Rate per 1000 person-years	10.13	6.76
HR (95% CI)	Reference	0.67 (0.55–0.82)
Baseline diuretic use
Patients, n	21 522	21 522
Person-years, n	15 543	17 851
Events, n	229	118
Rate per 1000 person-years	14.73	6.61
HR (95% CI)	Reference	0.45 (0.36–0.56)
No baseline diuretic use
Patients, n	97 936	97 936
Person-years, n	70 227	81 070
Events, n	427	363
Rate per 1000 person-years	6.08	4.48
HR (95% CI)	Reference	0.74 (0.64–0.85)

GLP1 = glucagon-like peptide-1; HR = hazard ratio; SGLT2 = sodium–glucose cotransporter-2.